Min-Han Tan/lucence.com
Jul 1, 2025, 19:06
Min-Han Tan Highlighted Medicare Coverage for LiquidHallmark ctDNA/ctRNA Liquid Biopsy
Min-Han Tan, Founder and CEO of Lucence, shared a post on LinkedIn by Mayo Clinic Laboratories, adding:
“ctDNA and ctRNA liquid biopsy is available now to help US cancer patients to help identify guideline recommended biomarkers.
LiquidHallmark ctDNA and ctRNA is the first such Medicare fully reimbursed test.
Very grateful to help advance liquid biopsy together with Mayo Clinic Laboratories!”
Quoting Mayo Clinic Laboratories’ post:
“Liquid biopsy cancer testing is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
Learn about patients who will benefit from the test and how an oncologist might use the results.”
Watch the video attached to this post.
More posts featuring Min-Han Tan on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 18, 2025, 14:47
Aug 18, 2025, 14:44
Aug 18, 2025, 14:33
Aug 18, 2025, 14:28
Aug 18, 2025, 14:23
Aug 18, 2025, 14:17
Aug 18, 2025, 14:13